AZTherapies Strengthens Neuroinflammation-Targeted Pipeline Through Acquisition of Smith Therapeutics
24 oct. 2019 08h32 HE
|
AZTherapies, Inc.
Cutting-edge CAR-Treg technology could have broad application across common and rare neurodegenerative diseases Smith Founder and CEO Philip Ashton-Rickardt, Ph.D. joins as SVP of Immunology ...
AZTherapies Closes $26.3 Million Series C Preferred Equity Financing
17 oct. 2019 08h32 HE
|
AZTherapies, Inc.
BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the closing of a $26.3 million Series C...
AZTherapies Announces Appointment of Pharma Industry Veteran George D. Behrakis to its Board of Directors
07 août 2019 08h32 HE
|
AZTherapies, Inc.
BOSTON, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced that investor, former...
AZTherapies Completes Enrollment in COGNITE Pivotal Phase 3 Trial of ALZT-OP1 for the Treatment of Early Alzheimer’s Disease
01 août 2019 08h32 HE
|
AZTherapies, Inc.
First-in-class candidate targets microglia to slow or halt neuroinflammation and disease progression ALZT-OP1 trial being conducted under an SPA with expected completion in late 2020 BOSTON, Aug. ...
AZTherapies Strengthens Management Team, Adding Industry Veteran Jay Mohr as Chief Operating and Business Officer, Head of Commercial Development
10 juil. 2019 08h32 HE
|
AZTherapies, Inc.
BOSTON, July 10, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the hiring of Jay Mohr as Chief Operating...
AZTherapies to Present at Maxim Group’s Conference on Alzheimer’s Disease
26 juin 2019 07h30 HE
|
AZTherapies, Inc.
Presentation to highlight Company’s late-stage clinical program and unique approach to neuroinflammation and the treatment of early Alzheimer’s disease BOSTON, June 26, 2019 (GLOBE NEWSWIRE) --...